Published in Gene Therapy Weekly, February 5th, 2004
FSMA and deCODE are making available deCODE's high-throughput screening capabilities to test promising compounds that may increase SMN (survival motor neuron) levels or supplement SMN function.
Using compounds identified through previous FSMA-funded research, deCODE's Chicago, Illinois-based pharmaceuticals group has completed initial screening and is now working to optimize hits to obtain...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.